Menu
Medicines at
the Nexus of
Metabolism &
Immunity
"Path to End Patient Suffering"
Nirogy Story & Vision
“Nirogy” means “without illness” in Sanskrit. Our vision is to create a path to end patient suffering. Nirogy has been trying to unravel the intricate symbiotic communication network among various cell types in the tumor and immune microenvironment (TIME)…
Nirogy Story & Vision
“Nirogy” means “without illness” in Sanskrit. Our vision is to create a path to end patient suffering. Nirogy has been trying to unravel the intricate symbiotic communication network among various cell types in the tumor and immune microenvironment (TIME)…
Transformative Science
A pioneer in the metabolic solute carrier transporter (SLCT) space, a largely untapped target class, for hard-to-treat diseases such as cancer, autoimmunity, and inflammation…
Passionate Team
An experienced team of science, business, and operations united by a common goal.
Nirogy News
Nirogy Therapeutics Opens New Lab and Office Space as Headquarters Near Boston to Expand Operations
BOSTON, July 15, 2021 – Nirogy Therapeutics Inc., a privately-held biotechnology company developing novel small molecules to target cellular transporters, today announced the opening of new 10,000 square foot laboratory …
Nirogy Therapeutics to Present at AACR Annual Meeting 2021
E-posters highlighting preclinical data demonstrate the potential of Nirogy’s small molecule therapies to enable significant activation of anti-tumor immunity and simultaneous killing of cancer cells in both in vitro and …
Market ‘Solutes’ Nirogy Small-Molecule Flag with $16.5M Series A
Boston-based Nirogy Therapeutics Inc.’s $16.5 million series A round is meant to enable a pipeline of small-molecule drugs targeting the solute carrier family of transporter proteins (SLCTs) embedded in the …
